X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Oil reserves, Indian pharma & more... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Feb 19, 2008

    Oil reserves, Indian pharma & more...

    • With the signs of a recession looming large over the US economy, the Federal Reserve and the policymakers are taking all steps necessary to prevent the American consumer from feeling the pinch of an economic slowdown. While the Fed has resorted to interest rate cuts to boost spending, the government has unveiled a package of tax rebates and temporary investment incentives worth US$ 152 bn or just over 1% of its GDP. But given the rising food and energy prices, the likelihood of stagflation seems to be more prominent.

      Juxtapose this against the economic environment in emerging economies, which are shying away from loose monetary policies largely due to inflationary concerns given the firm oil and food prices. Hence, the central banks in these countries and more notably in India, in a bid to contain inflation, are refraining from undertaking interest rate cuts. And very rightly so! This is despite the widening interest rate differential, which is likely to propel further foreign inflows.


    • Crude oil prices continue to hover on a higher terrain and the world's growing demand for the fuel has not helped matters. This means that oil-production will have to be stepped up a notch to bridge the demand supply gap. However, it is not as easy as it seems. While geopolitical issues, war and natural disasters tend to disrupt the supply of oil, many oil experts conclude that the world's oil reserves are depleting. Others claim that while oil is indeed finite, even now there is plenty of oil available. Only, it needs to be brought to the consumers. And therein lies the problem. New technologies would have to be employed to extract oil and convert it into a more usable form - a daunting task indeed. Also, much of what remains of oil lies in remote places making extraction of the same that much more difficult. As per reports published on CNN Money, a US government survey has said that the world has 3 trillion barrels of oil left as compared to the 1 trillion used so far in history.


    • One of the various reasons, which will contribute to the growth of the Indian pharma industry are the rising incomes that will increase the affordability of drugs. At present, India's per capita health expenditure in absolute terms is considerably lower in comparison to countries such as China, Brazil, Malaysia, Russia, the UK and the US. Around 80% of the healthcare payments are borne by the individual in India, as against the developed markets, where only 10% to 30% are borne by individuals. Therefore, besides intense competition, this fact also explains why India is a low-price, high-volume market. Unless a new drug provides a significant therapeutic use, the willingness to purchase a relatively high-priced drug is absent. Thus, for patented drugs to do well, there will have to be increased penetration of health insurance in the country and a significantly better therapeutic use of the patented product to justify the high premium for the same. In the long-term, healthcare expenditure is expected to increase in line with the growth in per-capita income.

      Another thing to be noted is that medical facilities are very outdated and unaffordable for a large-section of the Indian society (70% of the population lives in rural areas). So, by increasing penetration i.e., making adequate medical facilities available, volumes are expected to grow. Besides this, life-style related diseases would increase in line with urbanisation leading to a demand for chronic therapy-related drugs. Given the fact that the cost of medical care for chronic diseases such as diabetes and cardiovascular is higher than acute diseases such as fever, cough and cold, in value terms, Indian healthcare market will grow. This also explains the reason why most of the domestic companies are increasing the focus on lifestyle drugs.

     

     

    Equitymaster requests your view! Post a comment on "Oil reserves, Indian pharma & more...". Click here!

      
     

    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    Were You Lured By Mr Market's Bait? (The 5 Minute Wrapup)

    Aug 23, 2017

    Mr Market lured investors into believing they'd bitten into a crash. Did you take the bait?

    Deep State First (Vivek Kaul's Diary)

    Aug 23, 2017

    Nowhere was the darkness deeper than in the nation's capital. There, no light shone. No flicker of awareness...observation...learning...or reflection appeared.

    Why Hasn't Warren Buffett Rung the Bell Yet? (The 5 Minute Wrapup)

    Aug 22, 2017

    It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.

    Think Twice Before You Keep Money In A Savings Bank Account (Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE SENSEX


    Aug 24, 2017 09:20 AM

    MARKET STATS